Stockreport

Royalty Pharma Acquires Royalty Interest In Gavreto From Blueprint Medicines For Up To $340 Million [TheStreet.com]

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com
PDF Attractive, precision oncology therapy with long patent duration added to portfolio Blueprint Medicines to receive $175 million upfront and $165 million in potential mi [Read more]